The aims of this study were to determine if metabolic PET parameters, assessed at baseline and after 2 cycles of chemotherapy, and/or gene expression profile, assessed at the time of initial diagnostic biopsy, along with clinical and pathological characteristics, may improve the prediction of response to NAC and of the outcome in ER-positive HER2-negative luminal breast cancers patients. Here, ESR1 is linked to breast cancer.